AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (4.4 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

NAD+ supplementation augments the efficacy of the PARP1 inhibitor PJ34 in a 6-OHDA-induced model of Parkinson’s disease

Mengling Hua,b,c,f, Xiaoqian Lid,f, Dongsheng Fand,f, Lu Yuc, Fan Rene, Jianming Wuc, Jianing Mib, Yang Zhengc, Xiaogang Zhouc( ), Dalian Qinc( ), Anguo Wuc ( )
Department of Pharmacy, Guang’an People’s Hospital, Sichuan 638550, China
State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China
Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of Drug Clinical Trial/GCP Center, Department of Cardiology of The Affiliated Hospital of Southwest Medical University, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China
Department of Pharmacy, First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550000, China
Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China

f These authors contributed equally to this work.

Peer review under the responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Genes & Diseases
Volume 13 Issue 2,
March 2026
DOI: 10.1016/j.gendis.2025.101783

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Hu M, Li X, Fan D, et al. NAD+ supplementation augments the efficacy of the PARP1 inhibitor PJ34 in a 6-OHDA-induced model of Parkinson’s disease. Genes & Diseases, 2026, 13(2). https://doi.org/10.1016/j.gendis.2025.101783

224

Views

3

Downloads

1

Crossref

2

Web of Science

4

Scopus

0

CSCD
Received: 10 January 2025
Published: 25 July 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).